explore -WSS

explore

author：Wikipedia 2025-09-30 08:49:46 - browse：52444

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The United States must get value

WSS

Ripples from Flovent's discontinuation is killing children with asthma

Galapagos to make CAR

What a koala virus tells us about the human genome

With clinical trial data readouts, here's how to spot spin

STAT series 'Denied by AI' wins major journalism prizes

U.K. Biobank has 500,000 peoples' genome sequences available

hotspot

explore

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Supreme Court to hear if Covid misinformation is protected speech

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Despite FDA concern, risk that CAR

Guidelines to prevent youth baseball injuries need more muscle

30 years of 'Listening to Prozac'

Tori Bowie and the unacceptable rates of Black maternal death

Galapagos to make CAR

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Wikipedia

What don’t we know about an Alzheimer’s drug side effect?

U.K. Biobank has 500,000 peoples' genome sequences available

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Oak Street deal isn't the answer to health care's woes

Takeda, Janssen join wearable maker to measure scratching

Obesity drug from Roche shows promise in early study

entertainment

hotspot

entertainment

hotspot